50% response rate for Rina-S in Phase 1/2 ovarian cancer study; Phase 3 trial planned for 2024.
Rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate targeting folate receptor-alpha, showed a 50% objective response rate in advanced ovarian cancer patients during a Phase 1/2 study. Conducted with 42 patients, the trial indicated that 95% were platinum-resistant. Rina-S 120 mg/m² was selected for a Phase 3 trial expected to begin in 2024. Common side effects included anemia and nausea, but serious adverse events were minimal.
September 15, 2024
4 Articles